NasdaqGS - Nasdaq Real Time Price USD

Vir Biotechnology, Inc. (VIR)

8.23 +0.60 (+7.86%)
At close: April 26 at 4:00 PM EDT
8.22 -0.01 (-0.12%)
After hours: April 26 at 6:34 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
39,494.00
39,494.00
1,580,472.00
1,087,068.00
67,245.00
Cost of Revenue
2,765.00
2,765.00
146,319.00
65,865.00
--
Gross Profit
36,729.00
36,729.00
1,434,153.00
1,021,203.00
67,245.00
Operating Expense
721,034.00
721,034.00
601,085.00
600,452.00
364,225.00
Operating Income
-684,305.00
-684,305.00
833,068.00
420,751.00
-296,980.00
Net Non Operating Interest Income Expense
86,990.00
86,990.00
28,092.00
439.00
2,836.00
Other Income Expense
-30,879.00
-30,879.00
-106,880.00
128,612.00
-4,467.00
Pretax Income
-628,194.00
-628,194.00
754,280.00
549,802.00
-298,611.00
Tax Provision
-13,077.00
-13,077.00
238,443.00
21,218.00
54.00
Net Income Common Stockholders
-615,061.00
-615,061.00
515,837.00
528,584.00
-298,665.00
Diluted NI Available to Com Stockholders
-615,061.00
-615,061.00
515,837.00
528,584.00
-298,665.00
Basic EPS
-4.50
-4.59
3.89
4.07
-2.51
Diluted EPS
-4.50
-4.59
3.83
3.96
-2.51
Basic Average Shares
133,767.65
134,130.92
132,606.77
129,884.97
119,159.42
Diluted Average Shares
134,254.48
134,130.92
134,810.91
133,437.13
119,159.42
Total Operating Income as Reported
-684,305.00
-684,305.00
833,068.00
420,751.00
-296,980.00
Total Expenses
723,799.00
723,799.00
747,404.00
666,317.00
364,225.00
Net Income from Continuing & Discontinued Operation
-615,061.00
-615,061.00
515,837.00
528,584.00
-298,665.00
Normalized Income
-593,632.65
-593,632.65
591,856.76
395,918.91
-298,665.00
Interest Income
86,990.00
86,990.00
28,092.00
439.00
2,836.00
Net Interest Income
86,990.00
86,990.00
28,092.00
439.00
2,836.00
EBIT
-684,305.00
-684,305.00
833,068.00
420,751.00
-296,980.00
EBITDA
-664,854.00
-664,854.00
839,851.00
426,562.00
-291,538.00
Reconciled Cost of Revenue
2,765.00
2,765.00
146,319.00
65,865.00
--
Reconciled Depreciation
19,451.00
19,451.00
6,783.00
5,811.00
5,442.00
Net Income from Continuing Operation Net Minority Interest
-615,061.00
-615,061.00
515,837.00
528,584.00
-298,665.00
Total Unusual Items Excluding Goodwill
-21,888.00
-21,888.00
-111,140.00
138,049.00
--
Total Unusual Items
-21,888.00
-21,888.00
-111,140.00
138,049.00
--
Normalized EBITDA
-642,966.00
-642,966.00
950,991.00
288,513.00
-291,538.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-459.65
-459.65
-35,120.24
5,383.91
--
12/31/2020 - 10/11/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SAGE Sage Therapeutics, Inc.
13.69
+0.81%
 
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
 
RLAY Relay Therapeutics, Inc.
6.37
+3.49%
 
CVAC CureVac N.V.
2.3300
+0.87%
 
BLUE bluebird bio, Inc.
0.9228
+1.13%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
VERV Verve Therapeutics, Inc.
6.16
-0.96%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
 
ALEC Alector, Inc.
5.25
+9.15%
 
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%